Global Anthrax Treatment Market
Global Anthrax Treatment Market

Anthrax Treatment Comprehensive Study by Disease Type (Cutaneous Anthrax, Inhalation Anthrax, Gastrointestinal Anthrax, Injection Anthrax), Treatment (Antibiotics ( ciprofloxacin (Cipro), doxycycline (Vibramycin) and levofloxacin), Antitoxins (raxibacumab and obiltoxaximab), Surgery), End-user (Hospitals, Clinics, Ambulatory Surgical Centres, Others), Diagnosis (Blood Tests, Skin Tests, Stool Samples, Imaging Tests (CT Scan, X-ray), Endoscopy) Players and Region - Global Market Outlook to 2026

Anthrax Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2021 Edition 206 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Anthrax Treatment Market?

Anthrax is a serious infectious illness caused by the microbe Bacillus anthracis, a hardy, spore-forming bacterium that can survive in extreme conditions for a long time. This infection primarily affects livestock and wild game. It spreads through direct or indirect contact with sick animals. It is generally infected by eating contaminated meat or inhaling the spores. The standard treatment used for anthrax is an antibiotic that involves levofloxacin, doxycycline (Vibramycin) or ciprofloxacin (Cipro). The antitoxins are also used in the anthrax treatment such as raxibacumab and obiltoxaximab for inhalation anthrax.

The market study is being classified and major geographies with country level break-up.

Altimmune Inc. (United States), Elusys Therapeutics, Inc. (United States), Emergent BioSolutions, Inc. (United States), Porton Biopharma Limited (United Kingdom), Pfizer Inc. (United States), Bayer AG (Germany), GlaxoSmithKline plc (United Kingdom), Teva Pharmaceutical Industries Ltd (Israel) and Eli Lilly and Company (United States) are some of the key players profiled in the study.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Anthrax Treatment market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Anthrax Treatment market by Type, Application and Region.

On the basis of geography, the market of Anthrax Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Research Funding and the Development of the Novel Therapies
  • Growing Threat of Exposure among the Civilian Population and Military Forces

Market Trend
  • Increased Research and Development Activities

Restraints
  • Growing Resistance of Microorganisms against Drugs

Opportunities
  • Growth in the Healthcare Industry Worldwide
  • Increased Research and Development Investments by Major Players

Challenges
  • Stringent Government Rules and Regulations


Market Leaders and some development strategies
In June 2020, Altimmune, Inc., a clinical-stage biopharmaceutical company, has announced the dosing of the first patient in the Company’s Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. Compan's this program is being developed under a contract with the Biomedical Advanced Research and Development Authority (BARDA).



Key Target Audience
Anthrax Treatment Providers, Distributors, Emerging Companies, Research Professionals and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Disease Type
  • Cutaneous Anthrax
  • Inhalation Anthrax
  • Gastrointestinal Anthrax
  • Injection Anthrax

By Treatment
  • Antibiotics ( ciprofloxacin (Cipro), doxycycline (Vibramycin) and levofloxacin)
  • Antitoxins (raxibacumab and obiltoxaximab)
  • Surgery

By End-user
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centres
  • Others

By Diagnosis
  • Blood Tests
  • Skin Tests
  • Stool Samples
  • Imaging Tests (CT Scan, X-ray)
  • Endoscopy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Research Funding and the Development of the Novel Therapies
      • 3.2.2. Growing Threat of Exposure among the Civilian Population and Military Forces
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Anthrax Treatment, by Disease Type, Treatment, End-user, Diagnosis and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Anthrax Treatment (Value)
      • 5.2.1. Global Anthrax Treatment by: Disease Type (Value)
        • 5.2.1.1. Cutaneous Anthrax
        • 5.2.1.2. Inhalation Anthrax
        • 5.2.1.3. Gastrointestinal Anthrax
        • 5.2.1.4. Injection Anthrax
      • 5.2.2. Global Anthrax Treatment by: Treatment (Value)
        • 5.2.2.1. Antibiotics ( ciprofloxacin (Cipro), doxycycline (Vibramycin) and levofloxacin)
        • 5.2.2.2. Antitoxins (raxibacumab and obiltoxaximab)
        • 5.2.2.3. Surgery
      • 5.2.3. Global Anthrax Treatment by: End-user (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Ambulatory Surgical Centres
        • 5.2.3.4. Others
      • 5.2.4. Global Anthrax Treatment by: Diagnosis (Value)
        • 5.2.4.1. Blood Tests
        • 5.2.4.2. Skin Tests
        • 5.2.4.3. Stool Samples
        • 5.2.4.4. Imaging Tests (CT Scan, X-ray)
        • 5.2.4.5. Endoscopy
      • 5.2.5. Global Anthrax Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Anthrax Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Altimmune Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Elusys Therapeutics, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Emergent BioSolutions, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Porton Biopharma Limited (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bayer AG (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GlaxoSmithKline plc (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva Pharmaceutical Industries Ltd (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eli Lilly and Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Anthrax Treatment Sale, by Disease Type, Treatment, End-user, Diagnosis and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Anthrax Treatment (Value)
      • 7.2.1. Global Anthrax Treatment by: Disease Type (Value)
        • 7.2.1.1. Cutaneous Anthrax
        • 7.2.1.2. Inhalation Anthrax
        • 7.2.1.3. Gastrointestinal Anthrax
        • 7.2.1.4. Injection Anthrax
      • 7.2.2. Global Anthrax Treatment by: Treatment (Value)
        • 7.2.2.1. Antibiotics ( ciprofloxacin (Cipro), doxycycline (Vibramycin) and levofloxacin)
        • 7.2.2.2. Antitoxins (raxibacumab and obiltoxaximab)
        • 7.2.2.3. Surgery
      • 7.2.3. Global Anthrax Treatment by: End-user (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Ambulatory Surgical Centres
        • 7.2.3.4. Others
      • 7.2.4. Global Anthrax Treatment by: Diagnosis (Value)
        • 7.2.4.1. Blood Tests
        • 7.2.4.2. Skin Tests
        • 7.2.4.3. Stool Samples
        • 7.2.4.4. Imaging Tests (CT Scan, X-ray)
        • 7.2.4.5. Endoscopy
      • 7.2.5. Global Anthrax Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Anthrax Treatment: by Disease Type(USD Million)
  • Table 2. Anthrax Treatment Cutaneous Anthrax , by Region USD Million (2015-2020)
  • Table 3. Anthrax Treatment Inhalation Anthrax , by Region USD Million (2015-2020)
  • Table 4. Anthrax Treatment Gastrointestinal Anthrax , by Region USD Million (2015-2020)
  • Table 5. Anthrax Treatment Injection Anthrax , by Region USD Million (2015-2020)
  • Table 6. Anthrax Treatment: by Treatment(USD Million)
  • Table 7. Anthrax Treatment Antibiotics ( ciprofloxacin (Cipro), doxycycline (Vibramycin) and levofloxacin) , by Region USD Million (2015-2020)
  • Table 8. Anthrax Treatment Antitoxins (raxibacumab and obiltoxaximab) , by Region USD Million (2015-2020)
  • Table 9. Anthrax Treatment Surgery , by Region USD Million (2015-2020)
  • Table 10. Anthrax Treatment: by End-user(USD Million)
  • Table 11. Anthrax Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 12. Anthrax Treatment Clinics , by Region USD Million (2015-2020)
  • Table 13. Anthrax Treatment Ambulatory Surgical Centres , by Region USD Million (2015-2020)
  • Table 14. Anthrax Treatment Others , by Region USD Million (2015-2020)
  • Table 15. Anthrax Treatment: by Diagnosis(USD Million)
  • Table 16. Anthrax Treatment Blood Tests , by Region USD Million (2015-2020)
  • Table 17. Anthrax Treatment Skin Tests , by Region USD Million (2015-2020)
  • Table 18. Anthrax Treatment Stool Samples , by Region USD Million (2015-2020)
  • Table 19. Anthrax Treatment Imaging Tests (CT Scan, X-ray) , by Region USD Million (2015-2020)
  • Table 20. Anthrax Treatment Endoscopy , by Region USD Million (2015-2020)
  • Table 21. South America Anthrax Treatment, by Country USD Million (2015-2020)
  • Table 22. South America Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 23. South America Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 24. South America Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 25. South America Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 26. Brazil Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 27. Brazil Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 28. Brazil Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 29. Brazil Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 30. Argentina Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 31. Argentina Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 32. Argentina Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 33. Argentina Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 34. Rest of South America Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 35. Rest of South America Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 36. Rest of South America Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 37. Rest of South America Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 38. Asia Pacific Anthrax Treatment, by Country USD Million (2015-2020)
  • Table 39. Asia Pacific Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 40. Asia Pacific Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 41. Asia Pacific Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 42. Asia Pacific Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 43. China Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 44. China Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 45. China Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 46. China Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 47. Japan Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 48. Japan Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 49. Japan Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 50. Japan Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 51. India Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 52. India Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 53. India Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 54. India Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 55. South Korea Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 56. South Korea Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 57. South Korea Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 58. South Korea Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 59. Taiwan Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 60. Taiwan Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 61. Taiwan Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 62. Taiwan Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 63. Australia Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 64. Australia Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 65. Australia Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 66. Australia Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 71. Europe Anthrax Treatment, by Country USD Million (2015-2020)
  • Table 72. Europe Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 73. Europe Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 74. Europe Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 75. Europe Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 76. Germany Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 77. Germany Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 78. Germany Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 79. Germany Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 80. France Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 81. France Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 82. France Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 83. France Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 84. Italy Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 85. Italy Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 86. Italy Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 87. Italy Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 88. United Kingdom Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 89. United Kingdom Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 90. United Kingdom Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 91. United Kingdom Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 92. Netherlands Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 93. Netherlands Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 94. Netherlands Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 95. Netherlands Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 96. Rest of Europe Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 97. Rest of Europe Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 98. Rest of Europe Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 99. Rest of Europe Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 100. MEA Anthrax Treatment, by Country USD Million (2015-2020)
  • Table 101. MEA Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 102. MEA Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 103. MEA Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 104. MEA Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 105. Middle East Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 106. Middle East Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 107. Middle East Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 108. Middle East Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 109. Africa Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 110. Africa Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 111. Africa Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 112. Africa Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 113. North America Anthrax Treatment, by Country USD Million (2015-2020)
  • Table 114. North America Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 115. North America Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 116. North America Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 117. North America Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 118. United States Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 119. United States Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 120. United States Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 121. United States Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 122. Canada Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 123. Canada Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 124. Canada Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 125. Canada Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 126. Mexico Anthrax Treatment, by Disease Type USD Million (2015-2020)
  • Table 127. Mexico Anthrax Treatment, by Treatment USD Million (2015-2020)
  • Table 128. Mexico Anthrax Treatment, by End-user USD Million (2015-2020)
  • Table 129. Mexico Anthrax Treatment, by Diagnosis USD Million (2015-2020)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Anthrax Treatment: by Disease Type(USD Million)
  • Table 140. Anthrax Treatment Cutaneous Anthrax , by Region USD Million (2021-2026)
  • Table 141. Anthrax Treatment Inhalation Anthrax , by Region USD Million (2021-2026)
  • Table 142. Anthrax Treatment Gastrointestinal Anthrax , by Region USD Million (2021-2026)
  • Table 143. Anthrax Treatment Injection Anthrax , by Region USD Million (2021-2026)
  • Table 144. Anthrax Treatment: by Treatment(USD Million)
  • Table 145. Anthrax Treatment Antibiotics ( ciprofloxacin (Cipro), doxycycline (Vibramycin) and levofloxacin) , by Region USD Million (2021-2026)
  • Table 146. Anthrax Treatment Antitoxins (raxibacumab and obiltoxaximab) , by Region USD Million (2021-2026)
  • Table 147. Anthrax Treatment Surgery , by Region USD Million (2021-2026)
  • Table 148. Anthrax Treatment: by End-user(USD Million)
  • Table 149. Anthrax Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 150. Anthrax Treatment Clinics , by Region USD Million (2021-2026)
  • Table 151. Anthrax Treatment Ambulatory Surgical Centres , by Region USD Million (2021-2026)
  • Table 152. Anthrax Treatment Others , by Region USD Million (2021-2026)
  • Table 153. Anthrax Treatment: by Diagnosis(USD Million)
  • Table 154. Anthrax Treatment Blood Tests , by Region USD Million (2021-2026)
  • Table 155. Anthrax Treatment Skin Tests , by Region USD Million (2021-2026)
  • Table 156. Anthrax Treatment Stool Samples , by Region USD Million (2021-2026)
  • Table 157. Anthrax Treatment Imaging Tests (CT Scan, X-ray) , by Region USD Million (2021-2026)
  • Table 158. Anthrax Treatment Endoscopy , by Region USD Million (2021-2026)
  • Table 159. South America Anthrax Treatment, by Country USD Million (2021-2026)
  • Table 160. South America Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 161. South America Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 162. South America Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 163. South America Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 164. Brazil Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 165. Brazil Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 166. Brazil Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 167. Brazil Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 168. Argentina Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 169. Argentina Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 170. Argentina Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 171. Argentina Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 172. Rest of South America Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 173. Rest of South America Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 174. Rest of South America Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 175. Rest of South America Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 176. Asia Pacific Anthrax Treatment, by Country USD Million (2021-2026)
  • Table 177. Asia Pacific Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 178. Asia Pacific Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 179. Asia Pacific Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 180. Asia Pacific Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 181. China Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 182. China Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 183. China Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 184. China Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 185. Japan Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 186. Japan Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 187. Japan Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 188. Japan Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 189. India Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 190. India Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 191. India Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 192. India Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 193. South Korea Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 194. South Korea Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 195. South Korea Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 196. South Korea Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 197. Taiwan Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 198. Taiwan Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 199. Taiwan Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 200. Taiwan Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 201. Australia Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 202. Australia Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 203. Australia Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 204. Australia Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 205. Rest of Asia-Pacific Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 207. Rest of Asia-Pacific Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 208. Rest of Asia-Pacific Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 209. Europe Anthrax Treatment, by Country USD Million (2021-2026)
  • Table 210. Europe Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 211. Europe Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 212. Europe Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 213. Europe Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 214. Germany Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 215. Germany Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 216. Germany Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 217. Germany Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 218. France Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 219. France Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 220. France Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 221. France Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 222. Italy Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 223. Italy Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 224. Italy Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 225. Italy Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 226. United Kingdom Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 227. United Kingdom Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 228. United Kingdom Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 229. United Kingdom Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 230. Netherlands Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 231. Netherlands Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 232. Netherlands Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 233. Netherlands Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 234. Rest of Europe Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 235. Rest of Europe Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 236. Rest of Europe Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 237. Rest of Europe Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 238. MEA Anthrax Treatment, by Country USD Million (2021-2026)
  • Table 239. MEA Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 240. MEA Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 241. MEA Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 242. MEA Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 243. Middle East Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 244. Middle East Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 245. Middle East Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 246. Middle East Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 247. Africa Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 248. Africa Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 249. Africa Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 250. Africa Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 251. North America Anthrax Treatment, by Country USD Million (2021-2026)
  • Table 252. North America Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 253. North America Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 254. North America Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 255. North America Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 256. United States Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 257. United States Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 258. United States Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 259. United States Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 260. Canada Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 261. Canada Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 262. Canada Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 263. Canada Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 264. Mexico Anthrax Treatment, by Disease Type USD Million (2021-2026)
  • Table 265. Mexico Anthrax Treatment, by Treatment USD Million (2021-2026)
  • Table 266. Mexico Anthrax Treatment, by End-user USD Million (2021-2026)
  • Table 267. Mexico Anthrax Treatment, by Diagnosis USD Million (2021-2026)
  • Table 268. Research Programs/Design for This Report
  • Table 269. Key Data Information from Secondary Sources
  • Table 270. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Anthrax Treatment: by Disease Type USD Million (2015-2020)
  • Figure 5. Global Anthrax Treatment: by Treatment USD Million (2015-2020)
  • Figure 6. Global Anthrax Treatment: by End-user USD Million (2015-2020)
  • Figure 7. Global Anthrax Treatment: by Diagnosis USD Million (2015-2020)
  • Figure 8. South America Anthrax Treatment Share (%), by Country
  • Figure 9. Asia Pacific Anthrax Treatment Share (%), by Country
  • Figure 10. Europe Anthrax Treatment Share (%), by Country
  • Figure 11. MEA Anthrax Treatment Share (%), by Country
  • Figure 12. North America Anthrax Treatment Share (%), by Country
  • Figure 13. Global Anthrax Treatment share by Players 2020 (%)
  • Figure 14. Global Anthrax Treatment share by Players (Top 3) 2020(%)
  • Figure 15. Global Anthrax Treatment share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Altimmune Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Altimmune Inc. (United States) Revenue: by Geography 2020
  • Figure 19. Elusys Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Elusys Therapeutics, Inc. (United States) Revenue: by Geography 2020
  • Figure 21. Emergent BioSolutions, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Emergent BioSolutions, Inc. (United States) Revenue: by Geography 2020
  • Figure 23. Porton Biopharma Limited (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. Porton Biopharma Limited (United Kingdom) Revenue: by Geography 2020
  • Figure 25. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 27. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 29. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 31. Teva Pharmaceutical Industries Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 32. Teva Pharmaceutical Industries Ltd (Israel) Revenue: by Geography 2020
  • Figure 33. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 34. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 35. Global Anthrax Treatment: by Disease Type USD Million (2021-2026)
  • Figure 36. Global Anthrax Treatment: by Treatment USD Million (2021-2026)
  • Figure 37. Global Anthrax Treatment: by End-user USD Million (2021-2026)
  • Figure 38. Global Anthrax Treatment: by Diagnosis USD Million (2021-2026)
  • Figure 39. South America Anthrax Treatment Share (%), by Country
  • Figure 40. Asia Pacific Anthrax Treatment Share (%), by Country
  • Figure 41. Europe Anthrax Treatment Share (%), by Country
  • Figure 42. MEA Anthrax Treatment Share (%), by Country
  • Figure 43. North America Anthrax Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Altimmune Inc. (United States)
  • Elusys Therapeutics, Inc. (United States)
  • Emergent BioSolutions, Inc. (United States)
  • Porton Biopharma Limited (United Kingdom)
  • Pfizer Inc. (United States)
  • Bayer AG (Germany)
  • GlaxoSmithKline plc (United Kingdom)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Eli Lilly and Company (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation